Cargando…

Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK

AIM: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagshaw, Emma, Enoch, David A, Blackney, Michael, Posthumus, Jan, Kuessner, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190279/ https://www.ncbi.nlm.nih.gov/pubmed/29911889 http://dx.doi.org/10.2217/fmb-2018-0119

Ejemplares similares

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
por: Floros, Lefteris, et al.
Publicado: (2019)

Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2021)

Amphotericin-b-liposomal/isavuconazole: Lack of efficacy: case report
Publicado: (2021)

745. Combination Treatment of Liposomal Amphotericin B and Isavuconazole is Synergistic in Treating Experimental Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

850. Real-world effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients
por: Qiu, Ye, et al.
Publicado: (2023)

Amphotericin-B-liposomal/isavuconazole/voriconazole: Lack of efficacy: 6 case report
Publicado: (2022)

The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2022)

Isavuconazole for COVID-19-Associated Invasive Mold Infections
por: Ullah, Nadir, et al.
Publicado: (2022)

Breaking the mold: A case of pulmonary mucormycosis treated with isavuconazole
por: Huggins, Jonathan, et al.
Publicado: (2018)

Successful Multimodal Therapy with Intracerebral Liposomal Amphotericin B and Systemic High-Dose Isavuconazole in Proven Disseminated Aspergillosis
por: Feys, Simon, et al.
Publicado: (2023)

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales
por: Ortalli, Gaia, et al.
Publicado: (2023)

Isavuconazole and Liposomal Amphotericin B as Successful Combination Therapy of Refractory Invasive Candidiasis in a Liver Transplant Recipient: A Case Report and Literature Review
por: Odysseos, Georgios, et al.
Publicado: (2021)

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response
por: Kovanda, Laura L., et al.
Publicado: (2017)

Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of Exserohilum rostratum meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis
por: Petraitis, Vidmantas, et al.
Publicado: (2020)

Liposomal amphotericin B—the present
por: Maertens, J, et al.
Publicado: (2022)

Liposomal amphotericin B—the past
por: Brüggemann, R J, et al.
Publicado: (2022)

Liposomal amphotericin B—the future
por: Hoenigl, M, et al.
Publicado: (2022)

In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China
por: Jing, Ran, et al.
Publicado: (2022)

Isavuconazole for invasive fungal infections
Publicado: (2020)

Liposomal Amphotericin B Treatment and the Leishmaniases
por: Berman, Jonathan
Publicado: (2019)

Recurrent Candida albicans Ventriculitis Treated with Intraventricular Liposomal Amphotericin B
por: Toprak, Demet, et al.
Publicado: (2015)

EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
por: Jørgensen, Karin Meinike, et al.
Publicado: (2019)

Amphotericin-B/amphotericin-B-liposomal: Lack of efficacy: 2 case reports
Publicado: (2022)

845. Clinical Outcomes in Patients Treated with High vs. Standard Dose Liposomal Amphotericin B for Invasive Mucormycosis
por: Valiante, Sarah, et al.
Publicado: (2023)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

Amphotericin-B-liposomal: No improvement: case report
Publicado: (2022)

Amphotericin-B-liposomal: Anaphylaxis: case report
Publicado: (2022)

1149. Baseline Chest CT Findings in Patients with Pulmonary Mold Infections: A Post-Hoc Analysis from the Phase 3 SECURE Study that Compared Isavuconazole to Voriconazole for the Primary Treatment of Invasive Mold Disease
por: Hamed, Kamal, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

Role of isavuconazole in the treatment of invasive fungal infections
por: Wilson, Dustin T, et al.
Publicado: (2016)

Liposomal amphotericin B as a treatment for human leishmaniasis
por: Balasegaram, Manica, et al.
Publicado: (2012)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
por: Ubals, Maria, et al.
Publicado: (2021)

Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B
por: Armstrong-James, Darius, et al.
Publicado: (2020)

Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B
por: van de Peppel, Robert J, et al.
Publicado: (2020)

A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK
por: Bruynesteyn, Karin, et al.
Publicado: (2007)

Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
por: Miceli, Marisa H, et al.
Publicado: (2012)

In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates
por: Montagna, Maria Teresa, et al.
Publicado: (2014)

Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient
por: Anderson, Anthony, et al.
Publicado: (2017)

Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B
por: Kirchberger, Michael Constantin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pi9ekim98drapbd0o7meabfq02